CD8 T lymphocytes from immunologically stable HIV-1-infected secrete a soluble factor — termed CAF —, which suppresses HIV-1 replication, but the exact identity of CAF has been unclear. In September ...

Researchers discovered that interferon-stimulated SAMD9L restricts HIV-1 and other lentiviruses by inhibiting viral translation and endosomal trafficking, while SAMD9 enhances HIV-1 replication.

A chemical modification in the HIV-1 RNA genome whose function has been a matter of scientific debate is now confirmed to be key to the virus's ability to survive and thrive after infecting host ...

Recent studies highlight the role of nSMase2 in the late stages of HIV-1 replication, offering a novel antiretroviral target.

Analysts and charities have identified Gilead’s new HIV prevention injection as key to curbing infection rates.

It was previously demonstrated that the HIV-1 integrase (IN)-interacting host factor INI1/SMARCB1 binds to HIV-1 IN through its Rpt1 domain of INI1 (INI1-Rpt1) and plays a key role in assembly and ...

A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, ...

This could be a turning point, the scientists believe, as current treatments do not eradicate HIV but rather inhibit virus replication and delay onset.

PrEP reduces the risk of HIV, but current options need to be taken either daily in pill form or through an injection by a ...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the most undervalued quality stocks to buy according to hedge funds. On July 25, the European Medicines Agency’s Committee for Medicinal Products for Human ...